EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review

M Mansilla-Polo, E Gimeno, D Morgado-Carrasco

Actas Dermo-Sifiliográficas · 2024-03 · 115 (3) · T265-T279

DOI: 10.1016/j.ad.2024.01.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2024-03. Verfasst von M Mansilla-Polo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valenc…. Hauptthemen laut MEDLINE: Aminopyridines, Dermatology, Psoriasis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the treatment of plaque psoriasis and mild to moderate seborrheic dermatitis. Several studies have described the off-label use of roflumilast in dermatology, including a randomized controlled trial showing its usefulness in the treatment of psoriasis; case reports and small series have also reported successful outcomes in hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet disease. Roflumilast has a favorable safety profile, similar to that of apremilast, and it is considerably cheaper than new generation drugs and even some conventional immunosuppressants. We review the pharmacokinetics and pharmacodynamics of topical and oral roflumilast and discuss potential adverse effects and both approved and off-label uses in dermatology. Roflumilast is a promising agent to consider.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesDermatologyPsoriasisHumansBenzamidesCyclopropanesPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

ApremilastDermatologyDermatologíaFosfodiesterasaOff-labelPhosphodiesterasePsoriasisRoflumilast

Substanzen

AminopyridinesBenzamidesCyclopropanesRoflumilast

Autor:innen und Institutionen

  • Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain.
  • Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
  • Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain; Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Figueres, Girona, Spain. Electronic address: mo…

Zitieren

APA

Mansilla-Polo, M., Gimeno, E., & Morgado-Carrasco, D. (2024). [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review. Actas Dermo-Sifiliográficas, 115(3), T265-T279. https://doi.org/10.1016/j.ad.2024.01.009

Vancouver

Mansilla-Polo M, Gimeno E, Morgado-Carrasco D. [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review. Actas Dermo-Sifiliográficas. 2024;115(3):T265-T279. doi:10.1016/j.ad.2024.01.009

BibTeX
@article{MansillaPolo2024,
  author = {Mansilla-Polo, M and Gimeno, E and Morgado-Carrasco, D},
  title = {[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2024},
  volume = {115},
  number = {3},
  pages = {T265--T279},
  doi = {10.1016/j.ad.2024.01.009}
}
Kostenlos starten →